Management of osteoporosis in the aging male: Focus on zoledronic acid

Paul K Piper Jr1, Ugis Gruntmanis1,21Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX USA; 2North Texas Veterans Affairs Medical Center, Dallas, TX USAAbstract: Osteoporosis in the aging male remains an important yet under-recognized and undertrea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paul K Piper Jr, Ugis Gruntmanis
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Osteoporosis Aging Male zoledronic acid Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/e99d02c1bbae4937ba19d775b87ff477
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e99d02c1bbae4937ba19d775b87ff477
record_format	dspace
spelling	oai:doaj.org-article:e99d02c1bbae4937ba19d775b87ff4772021-12-02T01:02:55ZManagement of osteoporosis in the aging male: Focus on zoledronic acid1178-1998https://doaj.org/article/e99d02c1bbae4937ba19d775b87ff4772009-06-01T00:00:00Zhttps://www.dovepress.com/management-of-osteoporosis-in-the-aging-male-focus-on-zoledronic-acid-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Paul K Piper Jr1, Ugis Gruntmanis1,21Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX USA; 2North Texas Veterans Affairs Medical Center, Dallas, TX USAAbstract: Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.Keywords: male osteoporosis, bisphosphonates, zoledronic acidPaul K Piper JrUgis GruntmanisDove Medical PressarticleOsteoporosisAging Malezoledronic acidGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 289-303 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Osteoporosis Aging Male zoledronic acid Geriatrics RC952-954.6
spellingShingle	Osteoporosis Aging Male zoledronic acid Geriatrics RC952-954.6 Paul K Piper Jr Ugis Gruntmanis Management of osteoporosis in the aging male: Focus on zoledronic acid
description	Paul K Piper Jr1, Ugis Gruntmanis1,21Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX USA; 2North Texas Veterans Affairs Medical Center, Dallas, TX USAAbstract: Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.Keywords: male osteoporosis, bisphosphonates, zoledronic acid
format	article
author	Paul K Piper Jr Ugis Gruntmanis
author_facet	Paul K Piper Jr Ugis Gruntmanis
author_sort	Paul K Piper Jr
title	Management of osteoporosis in the aging male: Focus on zoledronic acid
title_short	Management of osteoporosis in the aging male: Focus on zoledronic acid
title_full	Management of osteoporosis in the aging male: Focus on zoledronic acid
title_fullStr	Management of osteoporosis in the aging male: Focus on zoledronic acid
title_full_unstemmed	Management of osteoporosis in the aging male: Focus on zoledronic acid
title_sort	management of osteoporosis in the aging male: focus on zoledronic acid
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/e99d02c1bbae4937ba19d775b87ff477
work_keys_str_mv	AT paulkpiperjr managementofosteoporosisintheagingmalefocusonzoledronicacid AT ugisgruntmanis managementofosteoporosisintheagingmalefocusonzoledronicacid
_version_	1718403351061725184

Management of osteoporosis in the aging male: Focus on zoledronic acid

Ejemplares similares